Abstract：Objective To compare target dosimetric distribution and normal tissue radiation between different static intensity-modulated radiation therapy (IMRT) plans and volumetric modulated arc therapy (VMAT) and to identify the best IMRT plan for patients with primary mediastinal B-cell lymphoma (PMBCL). Methods A total of 16 patients (8 males and 8 females) with early-stage (Ann-Arbor stage Ⅰ) PMBCL were enrolled in this study, with doses of 45 Gy for primary gross tumor volume (PGTV) and 40 Gy for planning target volume (PTV).Four plans were designed for each patient, consisting of static IMRT (5F-IMRT, 7F-IMRT, 9F-IMRT) and VMAT, and the target dosimetric distribution, normal tissue radiation dose, and efficiency of each plan were evaluated. The difference of dose was analyzed by analysis of variance. Results The mean conformity index (CI) and homogeneity index (HI) for PGTV in 5F-, 7F-, 9F-IMRT and VMAT were 1.01 and 1.10, 1.01 and 1.10, 1.01 and 1.10, and 1.01 and 1.11(P=0.963 and 0.843), respectively, while these two indices for PTV were 1.04 and 1.22, 1.03 and 1.19, 1.03 and 1.17, and 1.08 and 1.14(P=0.964 and 0.969), respectively. The parameters of volume and dose were similar on normal tissue (P=0.192-1.000).The treatment time and number of monitor units in 9F-IMRT were significantly higher than those in other static IMRT plans and VMAT (P=0.000, 0.000), and among these plans, VMAT had the lowest number of monitor units (13 345.0 MU) and the shortest treatment time (5.9 min). Conclusions The target volume coverage of 7F-and 9F-IMRT is better than that of 5F-IMRT and VMAT.For early-stage PMBCL, VMAT is not superior to IMRT in terms of dosimetry, especially with a larger area of low-dose radiation to the breast, but it is highly efficient in practice.
Xu Liming,Kang Minglei,Jiang Bo et al. Comparison of static intensity-modulated radiation therapy and volumetric modulated arc therapy in early-stage primary mediastinal B-cell lymphoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(6): 638-643.
[1] Cazals-Hatem D,Lepage E,Brice P,et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas,a GELA ±"Groupe d′Etude des Lymphomes de l′Adulte") study[J].Am J Surg Pathol,1996,20±7):877-888.DOI:10.1097/00000478-199607000-00012. [2] Rieger M, sterborg A,Pettengell R,et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab:results of the Mabthera International Trial Group study[J].Ann Oncol,2011,22(3):664-670.DOI:10.1093/annonc/mdq418. [3] Fietz T,Knauf WU,H nel M,et al. Treatment of primary mediastinal large B cell lymphoma with an alternating chemotherapy regimen based on high-dose methotrexate[J].Ann Hematol,2009,88(5):433-439.DOI:10.1007/s00277-008-0625-2. [4] Zinzani PL,Martelli M,Bertini M,et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis:a retrospective multinational study on 426 previously untreated patients[J].Haematologica,2002,87(12):1258-1264. [5] Mazzarotto R,Boso C,Vianello F,et al. Primary mediastinal large B-cell lymphoma:results of intensive chemotherapy regimens ±MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience[J].Int J Radiat Oncol Biol Phys,2007,68(3):823-829.DOI:10.1016/j.ijrobp.2006.12.048. [6] Zinzani PL,Stefoni V,Finolezzi E,et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma:a retrospective study[J].Clin Lymphoma Myeloma,2009,9(5):381-385.DOI:10.3816/CLM.2009.n.074. [7] Vassilakopoulos TP,Pangalis GA,Katsigiannis A,et al. Rituximab,cyclophosphamide,doxorubicin,vincristine,and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma:the emerging standard of care[J].Oncologist,2012,17(2):239-249.DOI:10.1634/theoncologist.2011-0275. [8] Goodman KA,Toner S,Hunt M,et al. Intensity-modulated radiotherapy for lymphoma involving the mediastinum[J].Int J Radiat Oncol Biol Phys,2005,62(1):198-206.DOI:10.1016/j.ijrobp.2004.08.048. [9] Girinsky T,van der Maazen R,Specht L,et al. Involved-node radiotherapy ±INRT) in patients with early Hodgkin lymphoma:concepts and guidelines[J].Radiother Oncol,2006,79(3):270-277.DOI:10.1016/j.radonc.2006.05.015. [10] Nieder C,Schill S,Kneschaurek P,et al. Comparison of three different mediastinal radiotherapy techniques in female patients:impact on heart sparing and dose to the breasts[J].Radiother Oncol,2007,82(3):301-307.DOI:10.1016/j.radonc.2006.10.015. [11] Paumier A,Ghalibafian M,Gilmore J,et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin′s lymphoma[J].Int J Radiat Oncol Biol Phys,2012,82(4):1522-1527.DOI:10.1016/j.ijrobp.2011.05.015. [12] Koeck J,Abo-Madyan Y,Lohr F,et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group ±GHSG):the roles of intensity-modulated radiotherapy and involved-node radiotherapy[J].Int J Radiat Oncol Biol Phys,2012,83(1):268-276.DOI:10.1016/j.ijrobp.2011.05.054. [13] Lu NN,Li YX,Wu RY,et al. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin′s lymphoma with mediastinal involvement[J].Int J Radiat Oncol Biol Phys,2012,84(1):210-216.DOI:10.1016/j.ijrobp.2011.11.008. [14] Xu LM,Fang H,Wang WH,et al. Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy[J].Leuk Lymphoma,2013,54(8):1684-1690.DOI:10.3109/10428194.2012.746684. [15] Xu LM,Li YX,Fang H,et al. Dosimetric evaluation and treatment outcome of intensity modulated radiation therapy after doxorubicin-based chemotherapy for primary mediastinal large B-cell lymphoma[J].Int J Radiat Oncol Biol Phys,2013,85(5):1289-1295.DOI:10.1016/j.ijrobp.2012.10.037. [16] Gaulard P,Harris NL,Pileri SA,et al. Primary mediastinal ±thymic) large B-cell lymphoma[A]//Jaffe ES,Harris NL,Stein H,et al. World Health Organization Classification of Tumours:pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues[M].Lyon,France:IARC Press,2008:250-251. [17] Yahalom J,Mauch P.The involved field is back:issues in delineating the radiation field in Hodgkin′s disease[J].Ann Oncol,2002,13 Suppl 1:79-83. [18] 张彦新,戴建荣,李明辉,等.一种估算静态MLC调强放疗治疗时间的方法[J].中国医学物理学杂志,2011,28(4):2736-2740.DOI:10.3969/j.issn.1005-202X.2011.04.009. [19] Koh ES,Sun A,Tran TH,et al. Clinical dose-volume histogram analysis in predicting radiation pneumonitis in Hodgkin′s lymphoma[J].Int J Radiat Oncol Biol Phys,2006,66(1):223-228.DOI:10.1016/j.ijrobp.2006.03.063. [20] Fox AM,Dosoretz AP,Mauch PM,et al. Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy[J].Int J Radiat Oncol Biol Phys,2012,83(1):277-283.DOI:10.1016/j.ijrobp.2011.05.078. [21] Otto K.Volumetric modulated arc therapy:IMRT in a single gantry arc[J].Med Phys,2008,35(1):310-317.DOI:10.1118/1.2818738. [22] Kuo YC,Chiu YM,Shih WP,et al. Volumetric intensity-modulated Arc ±RapidArc) therapy for primary hepatocellular carcinoma:comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy[J].Radiat Oncol,2011,6:76.DOI:10.1186/1748-717X-6-76. [23] Jeong Y,Lee SW,Kwak J,et al. A dosimetric comparison of volumetric modulated arc therapy ±VMAT) and non-coplanar intensity modulated radiotherapy ±IMRT) for nasal cavity and paranasal sinus cancer[J].Radiat Oncol,2014,9:193.DOI:10.1186/1748-717X-9-193. [24] Fiandra C,Filippi AR,Catuzzo P,et al. Different IMRT solutions vs.3D-conformal radiotherapy in early stage Hodgkin′s Lymphoma:dosimetric comparison and clinical considerations[J].Radiat Oncol,2012,7:186.DOI:10.1186/1748-717X-7-186. [25] Jiang XQ,Li T,Liu YM,et al. Planning analysis for locally advanced lung cancer:dosimetric and efficiency comparisons between intensity-modulated radiotherapy ±IMRT),single-arc/partial-arc volumetric modulated arc therapy ±SA/PA-VMAT)[J].Radiat Oncol,2011,6:140.DOI:10.1186/1748-717X-6-140. [26] Lin CY,Huang WY,Jen YM,et al. Dosimetric and efficiency comparison of high-dose radiotherapy for esophageal cancer:volumetric modulated arc therapy versus fixed-field intensity-modulated radiotherapy[J].Dis Esophagus,2014,27(6):585-590.DOI:10.1111/dote.12144. [27] Quan EM,Li XQ,Li YP,et al. A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment[J].Int J Radiat Oncol Biol Phys,2012,83(4):1169-1178.DOI:10.1016/j.ijrobp.2011.09.015. [28] Valakh V,Chan P,D′Adamo K,et al. Early-stage central lung cancer and volumetric modulated arc therapy:a dosimetric case study with literature review[J].Anticancer Res,2013,33(10):4491-4495. [29] Haciislamoglu E,Colak F,Canyilmaz E,et al. Dosimetric comparison of left-sided whole-breast irradiation with 3DCRT,forward-planned IMRT,inverse-planned IMRT,helical tomotherapy,and volumetric arc therapy[J].Phys Med,2015,31(4):360-367.DOI:10.1016/j.ejmp.2015.02.005. [30] Wu SG,Lai YQ,He ZY,et al. Dosimetric comparison of the simultaneous integrated boost in whole-breast irradiation after breast-conserving surgery:IMRT,IMRT plus an electron boost and VMAT[J/OL].PLoS One,2015,10(3):e0120811.DOI:10.1371/journal.pone.0120811. [31] Zhang Q,Yu XL,Hu WG,et al. Dosimetric comparison for volumetric modulated arc therapy and intensity-modulated radiotherapy on the left-sided chest wall and internal mammary nodes irradiation in treating post-mastectomy breast cancer[J].Radiol Oncol,2015,49(1):91-98.DOI:10.2478/raon-2014-0033.
2015, Vol. 24 
